Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFIK ABADIER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1649253147
CMS profile
256213
Location
INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,012.13

30 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,299.92 4
Food and Beverage $712.21 26

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFIK ABADIER

NPI 1649253147 · CMS profile ID 256213

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649253147?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649253147?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649253147?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1649253147?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

30 matching records · $2,012.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 30 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–30 of 30.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $16.2212/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673716451 CMS
Novartis Pharmaceuticals Corporation $16.8811/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103341 CMS
Medtronic Vascular, Inc. $19.8510/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 629258785 CMS
Medtronic Vascular, Inc. $14.0010/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 629258787 CMS
PFIZER INC. $12.5510/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673171045 CMS
BIOTRONIK INC. $21.4909/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701549975 CMS
Novartis Pharmaceuticals Corporation $15.1609/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103335 CMS
AstraZeneca Pharmaceuticals LP $13.9008/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685396407 CMS
Novartis Pharmaceuticals Corporation $17.1408/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103329 CMS
PFIZER INC. $20.4108/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672517429 CMS
PFIZER INC. $15.1506/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672070561 CMS
Janssen Pharmaceuticals, Inc $11.9205/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658245033 CMS
Janssen Pharmaceuticals, Inc $13.3504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658245031 CMS
PFIZER INC. $16.8504/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671981649 CMS
Novartis Pharmaceuticals Corporation $15.4204/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103323 CMS
Novartis Pharmaceuticals Corporation $12.0803/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103319 CMS
Amgen Inc. $17.5802/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662891599 CMS
Boston Scientific Corporation $36.3302/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662866047 CMS
PFIZER INC. $18.7502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671870689 CMS
PFIZER INC. $13.2101/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671854531 CMS
Amgen Inc. $23.1101/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343049 CMS
Amgen Inc. $46.2301/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343053 CMS
Amgen Inc. $23.1101/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343057 CMS
Amgen Inc. $853.9201/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343035 CMS
Amgen Inc. $123.8801/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343039 CMS
Amgen Inc. $152.1001/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343043 CMS
Amgen Inc. $112.9401/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343047 CMS
Amgen Inc. $170.0201/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343061 CMS
Amgen Inc. $149.4501/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663343064 CMS
Novartis Pharmaceuticals Corporation $19.1301/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659103313 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,012.13 30
PY2020 $285.07 11
PY2021 $127.23 4
PY2022 $153.51 10
PY2023 $3,321.33 24
PY2024 $2,191.02 22
PY2025 $222.26 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $731.79 4
PY2025 Principal investigator $554,369.24 96
PY2024 Principal investigator $1,358,878.08 258
PY2023 Principal investigator $1,095,651.17 1,020
PY2022 Principal investigator $767,493.58 1,505
PY2021 Principal investigator $331,251.89 220
PY2020 Principal investigator $152,753.28 147
PY2019 Principal investigator $85,046.12 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

147 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203467
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203469
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203473
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203477
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203481
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203485
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203488
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203491
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 12/23/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737203495
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 12/08/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906767
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7,624.33 11/30/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756027
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199231
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199233
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199237
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199239
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199245
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 11/19/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199247
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906593
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906595
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906597
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906599
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906601
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906603
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 11/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906605
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,574.60 10/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756025
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195207
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195211
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195215
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195221
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195223
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195227
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195231
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 10/20/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195235
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/24/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737193791
Principal investigator 1 Esperion Therapeutics, Inc. $250.00 09/22/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737193147
Principal investigator 1 Boehringer Ingelheim International GmbH $977.50 09/17/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906621
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190907
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190911
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190915
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190921
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190923
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190929
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190931
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 09/17/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737190935
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906615
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906617
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 09/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906619
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,049.73 08/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756023
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906625
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906627
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906629
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906653
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906655
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906773
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 08/11/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906781
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 08/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906657
Principal investigator 1 Boehringer Ingelheim International GmbH $842.00 08/04/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906623
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,558.02 07/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756017
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,165.78 07/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756021
Principal investigator 1 Boehringer Ingelheim International GmbH $92.70 07/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906607
Principal investigator 1 Boehringer Ingelheim International GmbH $92.70 07/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906609
Principal investigator 1 Boehringer Ingelheim International GmbH $37.08 07/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906611
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 07/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906613
Principal investigator 1 Boehringer Ingelheim International GmbH $18.54 07/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906771
Principal investigator 1 Boehringer Ingelheim International GmbH $415.05 06/23/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906659
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 05/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756019
Principal investigator 1 Boehringer Ingelheim International GmbH $1,260.00 05/26/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906591
Principal investigator 1 Boehringer Ingelheim International GmbH $277.00 05/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906783
Principal investigator 1 Boehringer Ingelheim International GmbH $1,335.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906581
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906635
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906637
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906639
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906641
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906643
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906645
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906647
Principal investigator 1 Boehringer Ingelheim International GmbH $116.00 04/21/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906649
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 04/09/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906631
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 04/09/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906633
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 04/09/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906651
Principal investigator 1 Boehringer Ingelheim International GmbH $40.62 04/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906583
Principal investigator 1 Boehringer Ingelheim International GmbH $50.77 04/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906585
Principal investigator 1 Boehringer Ingelheim International GmbH $20.31 04/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906587
Principal investigator 1 Boehringer Ingelheim International GmbH $5.48 04/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906589
Principal investigator 1 Amgen Inc. $255.00 03/27/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 731632217
Principal investigator 1 Boehringer Ingelheim International GmbH $1,662.00 03/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906715
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 03/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906717
Principal investigator 1 Boehringer Ingelheim International GmbH $120.00 03/10/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906719
Principal investigator 1 Boehringer Ingelheim International GmbH $10.33 03/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906741
Principal investigator 1 Boehringer Ingelheim International GmbH $10.33 03/03/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906743
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,082.89 02/29/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756015
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 02/26/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
PROSPECTIVE COMPARISON OF COMBINED ANGIOTENSIN NEPRILYSIN INHIBITION WITH LCZ696 RELATIVE TO ENALAPRIL ON CENTRAL AORTIC STIFFNESS AND VENTRICULAR VASCULAR COUPLING IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION No dispute reported 06/30/2026 721493817
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/25/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906709
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906695
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906697
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906699
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906701
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906703
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906705
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906707
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906711
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906713
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906721
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906723
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906725
Principal investigator 1 Boehringer Ingelheim International GmbH $920.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906727
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906729
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906731
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906733
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906735
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906737
Principal investigator 1 Boehringer Ingelheim International GmbH $849.00 02/18/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906739
Principal investigator 1 Boehringer Ingelheim International GmbH $40.95 02/05/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906761
Principal investigator 1 Boehringer Ingelheim International GmbH $61.43 02/05/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906763
Principal investigator 1 Boehringer Ingelheim International GmbH $102.39 02/05/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906765
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 02/05/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906779
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,077.48 02/05/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A MULTICENTER RANDOMIZED DOUBLE BLIND ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECTS OF LCZ696 COMPARED TO VALSARTAN ON COGNITIVE FUNCTION AS ASSESSED BY COMPREHENSIVE NEUROCOGNITIVE BATTERY AND BRAIN AMYLOID PLAQUE DEPOSITION AS ASSESSED BY PET IMAGING No dispute reported 06/30/2026 721493815
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7,624.33 01/31/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 750756013
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906673
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906675
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906677
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906679
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906681
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906683
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906685
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906687
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906689
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906691
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906693
Principal investigator 1 Boehringer Ingelheim International GmbH $1,245.00 01/14/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906769
Principal investigator 1 Amgen Inc. $4.50 01/09/2020 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 731632213
Principal investigator 1 Boehringer Ingelheim International GmbH $51.73 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906745
Principal investigator 1 Boehringer Ingelheim International GmbH $62.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906747
Principal investigator 1 Boehringer Ingelheim International GmbH $62.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906749
Principal investigator 1 Boehringer Ingelheim International GmbH $62.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906751
Principal investigator 1 Boehringer Ingelheim International GmbH $62.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906753
Principal investigator 1 Boehringer Ingelheim International GmbH $78.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906755
Principal investigator 1 Boehringer Ingelheim International GmbH $78.08 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906757
Principal investigator 1 Boehringer Ingelheim International GmbH $11.16 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906759
Principal investigator 1 Boehringer Ingelheim International GmbH $51.73 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906775
Principal investigator 1 Boehringer Ingelheim International GmbH $103.46 01/06/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906777
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 749906661
Principal investigator 1 Boehringer Ingelheim International GmbH $1,310.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906663
Principal investigator 1 Boehringer Ingelheim International GmbH $1,096.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906665
Principal investigator 1 Boehringer Ingelheim International GmbH $1,096.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906667
Principal investigator 1 Boehringer Ingelheim International GmbH $1,310.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906669
Principal investigator 1 Boehringer Ingelheim International GmbH $1,310.00 01/02/2020 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 749906671